🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 25 of 28

  1. TG-1801

    TG THERAPEUTICS, INC.

    B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  2. TGI-5

    TG THERAPEUTICS, INC.

    CRC (Colorectal Cancer)

    phase 1 small molecule active

    1 trial

  3. TGI-6 Injection

    TG THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  4. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 1 small molecule completed

    1 trial

  5. TGR-1202

    TG THERAPEUTICS, INC.

    Non-Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  6. TGR-1202

    TG THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  7. TGR-1202 + Obinutuzumab + Chlorambucil

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  8. TGR-1202 + brentuximab vedotin

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  9. TH1902

    WINDTREE THERAPEUTICS INC /DE/

    Solid Tumor

    phase 1 small molecule active

    1 trial

  10. TIL

    Iovance Biotherapeutics B.V.

    Sarcoma

    phase 1 small molecule completed

    1 trial

  11. TPST-1495 twice daily

    Tempest Therapeutics

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  12. TRIN2755

    BRIGHT MINDS BIOSCIENCES INC.

    Neoplasms

    phase 1 small molecule active

    1 trial

  13. TRU-016

    Aptevo Therapeutics

    B-cell Small Lymphocytic Lymphoma Recurrent

    phase 1 small molecule completed

    1 trial

  14. TRU-016 (anti-CD37 protein therapeutic)

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 1 small molecule completed

    1 trial

  15. TRUQAP 200 mg film-coated tablets, Faslodex 250 mg solution for injection., TRUQAP 160 mg film-coated tablets, PACLITAXEL, IMFINZI 50 mg/mL concentrate for solution for infusion., Capecitabine Accord 500 mg film-coated tablets, Capecitabine Accord 150 mg film-coated tablets, DS-8201a, Arimidex® 1 mg film-coated tablets

    AstraZeneca AB

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  16. TSB-9-W1

    Biotech Pharmaceutical Co.,

    Metastatic Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  17. TSC-204-A0201

    TScan Therapeutics

    Head and Neck Cancer

    phase 1 mab active

    1 trial

  18. TTI-101

    Tvardi Therapeutics

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  19. TTI-101

    Tvardi Therapeutics

    Breast Cancer

    phase 1 small molecule completed

    2 trials

  20. TTP607

    vTv Therapeutics

    Advanced Cancers

    phase 1 small molecule terminated

    1 trial

  21. TTX-MC138-NODAGA-Cu64

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  22. TVB-2640

    Sagimet Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule active

    1 trial

  23. TVB-2640

    Sagimet Biosciences

    Solid Malignant Tumor

    phase 1 small molecule completed

    1 trial

  24. TYRA-430

    Tyra Biosciences

    Metastatic Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  25. Ta-NPs (2% Tumor Volume)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Recurrent Retroperitoneal Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  26. Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma

    Disc Medicine

    Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2, Lymphoma

    phase 1 other active

    1 trial

  27. Talabostat Mesylate

    BioXcel Therapeutics

    Cancer of Pancreas

    phase 1 small molecule terminated

    1 trial

  28. Talazoparib

    BioMarin Pharmaceutical Australia Pty Ltd

    Childhood Solid Tumors

    phase 1 small molecule completed

    1 trial

  29. Target CD7 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  30. Targeted CEA CAR-T

    Chongqing Precision Biotech Co., Ltd

    Advanced Lung Cancer

    phase 1 mab active

    4 trials

  31. Tarlatamab

    BEONE MEDICINES AUS PTY LTD

    Extensive Stage Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  32. Tarlatamab

    Amgen

    Neuroendocrine Prostate Cancer

    phase 1 small molecule completed

    1 trial

  33. Tcrx T cell

    TScan Therapeutics

    Gastric Cancer

    phase 1 mab active

    1 trial

  34. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  35. Tepotinib

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  36. The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

    Sinobioway Cell Therapy Co.,

    Lymphoma

    phase 1 mab active

    1 trial

  37. The detection of tumor-associated fibrosis in colorectal peritoneal metastases by FAPI-PET (TROMPET)

    Disc Medicine

    Metastatic colorectal cancer

    phase 1 other active

    1 trial

  38. The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

    Lacuna Pharma Pty Ltd

    Relapsed and/or Refractory B-cell Lymphoma

    phase 1 other active

    1 trial

  39. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  40. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  41. ThisCART19A

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  42. ThisCART7 cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  43. Tipifarnib

    Kura Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  44. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  45. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  46. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial

  47. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  48. Trastuzumab Deruxtecan, and pembrolizumab in participants with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

    Daiichi Sankyo

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.